Palvella Therapeutics (PVLA) COO exercises options and sells 4,302 shares
Rhea-AI Filing Summary
Palvella Therapeutics Chief Operating Officer Kathleen Goin exercised stock options to acquire 4,302 shares of common stock on March 18, 2026 at exercise prices of $7.14 and $9.08 per share. She then sold 4,302 shares in three open-market transactions at weighted average prices of $117.5632, $118.3681, and $119.0817, as disclosed in the footnotes. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 19, 2025. Following the transactions, the report shows she holds no shares of Palvella Therapeutics common stock directly and no remaining derivative positions from these options.
Positive
- None.
Negative
- None.
Insights
COO executes a pre-planned exercise-and-sell, ending with no common shares held.
The transactions show a classic exercise-and-sell pattern. Kathleen Goin exercised options for 4,302 shares at strike prices of $7.14 and $9.08, then sold the same 4,302 shares in the market around $117–$119. This converts her option value into cash rather than increasing long-term equity exposure.
The filing specifies all trades occurred under a Rule 10b5-1 trading plan adopted on August 19, 2025, indicating they were pre-scheduled during an open trading window. That framing makes the timing more routine. After these transactions, her reported direct common stock position is zero, and derivativeSummary is empty, so no remaining options are shown in this report.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,154 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 2,148 | $0.00 | -- |
| Exercise | Common Stock | 2,154 | $7.14 | $15K |
| Exercise | Common Stock | 2,148 | $9.08 | $20K |
| Sale | Common Stock | 2,268 | $117.5632 | $267K |
| Sale | Common Stock | 1,730 | $118.3681 | $205K |
| Sale | Common Stock | 304 | $119.0817 | $36K |
Footnotes (1)
- The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $116.995 to $117.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.00 to $118.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $119.08 to $119.3767, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The stock option is fully vested.
